Dr Lal Path Labs reports consolidated Q2 FY26 PAT at Rs. 150.6 Cr

The company has posted net profit of Rs. 283 crore for the 6 months period ended September 30, 2025

Indegene posts consolidated Q2 FY26 PAT at Rs. 102.1 Cr

Dr Agarwals Health Care posts consolidated Q2 FY26 PAT at Rs. 29.69 Cr

Dr Agarwals Health Care has reported total income of Rs. 506.62 crore during the period ended September 30, 2025

Dabur India reports consolidated Q2 FY26 PAT at Rs. 452.55 Cr

Dabur India has reported total income of Rs. 3,331.45 crore during the period ended September 30, 2025

Dr. Agarwals Eye Hospital posts consolidated Q2 FY26 PAT at Rs. 19.32 Cr

Dr Agarwals Eye Hospital has reported total income of Rs. 118.40 crore during the period ended September 30, 2025

Cipla posts consolidated Q2 FY26 PAT Rs. 1,351.17 Cr

Cipla has reported total income of Rs. 7,858.39 crore during the period ended September 30, 2025

Tatva Chintan Pharma Chem reports consolidated Q2 FY26 PAT at Rs. 9.91 Cr

Tatva Chintan Pharma Chem has reported total income of Rs. 124.52 crore during the period ended September 30, 2025

Indraprastha Medical Corporation posts consolidated Q2 FY26 PAT at Rs. 49.46 Cr

Indraprastha Medical Corporation has reported total income of Rs. 388.40 crore during the period ended September 30, 2025

MedPlus Health Services posts consolidated Q2 FY26 PAT at Rs. 55.50 Cr

Medplus Health Services has reported total income of Rs. 1,696.79 crore during the period ended September 30, 2025

Bristol Myers Squibb posts Q3 2025 revenues $12.2 billion

Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development